Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 9/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL77520 | 0.84 | SMN1; SMN2 (0.67) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL19023194 | 0.83 | SMN1; SMN2 (0.62) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL13677224 | 0.82 | SMN1; SMN2 (0.64) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL13676897 | 0.81 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL1320183 | 0.81 | SMN1; SMN2 (0.65) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL7497263 | 0.81 | SMN1; SMN2 (0.62) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL19023772 | 0.81 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL19023351 | 0.80 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL4111065 | 0.80 | HTT (0.65) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL19023388 | 0.80 | SMN1; SMN2 (0.64) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120129855-A1 | PHTHALAZINONE DERIVATIVES | MENEAR KEITH ALLAN (GB) | 2012-05-24 | — | — | US | disclosed |
| US-20120129855-A1 | PHTHALAZINONE DERIVATIVES | MENEAR KEITH ALLAN (GB) | 2012-05-24 | — | — | US | disclosed |
| US-20120129855-A1 | PHTHALAZINONE DERIVATIVES | MENEAR KEITH ALLAN (GB) | 2012-05-24 | — | — | US | disclosed |
| US-8129380-B2 | Phthalazinone derivatives | ASTRAZENECA AB (SE) | 2012-03-06 | — | — | US | disclosed |
| US-8129380-B2 | Phthalazinone derivatives | ASTRAZENECA AB (SE) | 2012-03-06 | — | — | US | disclosed |
| US-8129380-B2 | Phthalazinone derivatives | ASTRAZENECA AB (SE) | 2012-03-06 | — | — | US | disclosed |
| EP-2231638-A1 | PHTHALAZINONE DERIVATIVES | AstraZeneca AB (SE) | 2010-09-29 | — | — | EP | disclosed |
| US-20090192156-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| US-20090192156-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| US-20090192156-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| WO-2009093032-A1 | PHTHALAZINONE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192156-A1 | PHTHALAZINONE DERIVATIVES | CBR1, CBR3, SDHA | SMN1; SMN2 3505/4885NPC1 1819/4885RAB9A 2944/4885 |
| US-20120129855-A1 | PHTHALAZINONE DERIVATIVES | CBR1, CBR3, SDHA | SMN1; SMN2 3505/4885NPC1 1819/4885RAB9A 2944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.